Randomized, Phase 3, Placebo-Controlled Double-Blind, Multicenter Trial of a One Time Intracoronary Administration of Ad5.hAC6 Gene Transfer for Patients With Reduced Left Ventricular Heart Failure
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2018
At a glance
- Drugs RT 100 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms FLOURISH
- Sponsors Renova Therapeutics
- 11 Jan 2018 According to a Renova Therapeutics media release, an overview of this trial will be presented at the Keystone Symposium on Heart Failure.
- 14 Dec 2017 According to a Renova Therapeutics media release, this trial is expected to begin in Q1 2018.
- 27 Nov 2017 Status changed from planning to not yet recruiting.